Recently, an independent team confirmed that AhR inhibition is reachable in vivo using other AhR antagonists (Kyn 101, Ikena Oncology, or the CH‐223191; Campesato et al,2020) to improve the melanoma therapy. This evidence concerns the gene AHR and melanoma.